Baxalta Reports Continued Progress on Phase 1/2 Clinical Trial of BAX335, Investigational Gene Therapy Treatment for Hemophilia B
June 24, 2015 at 09:01 AM EDT
Baxalta Incorporated, a wholly-owned subsidiary of Baxter International Inc. (NYSE: BAX), today reported continued progress on the Phase ...
